1
Clinical Trials associated with Pandemic Flu H5 mRNA Vaccine(Sanofi Pasteur) / Active, not recruitingPhase 1/2 A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development.
The duration per participant will be approximately 13 months.
100 Clinical Results associated with Pandemic Flu H5 mRNA Vaccine(Sanofi Pasteur)
100 Translational Medicine associated with Pandemic Flu H5 mRNA Vaccine(Sanofi Pasteur)
100 Patents (Medical) associated with Pandemic Flu H5 mRNA Vaccine(Sanofi Pasteur)
100 Deals associated with Pandemic Flu H5 mRNA Vaccine(Sanofi Pasteur)